BioEsol - The Company That Started Selling Batteries and Ended Up Looking Like a Fintech
How BioEsol is turning fragmented C&I energy demand into contracted, financeable infrastructure and building the capital stack to scale it.
Halfway through a call with Felipe Arriola, BioEsol’s president, something clicks: BioEsol may have started with batteries, but the ambition was always broader, to build a flexible energy-infrastructure platform around generation, storage and intelligent energy management.
The company develops, finances, deploys and operates distributed energy infrastructure for commercial and industrial customers in Mexico, one of the world’s most attractive markets for distributed energy, where industrial growth, grid constraints and rising power demand are converging, using an intentionally asset-light model built around strategic partners, leading equipment manufacturers, alliances and its own operating technology.
The biggest shift came from financing. BioEsol initially expected banks and financial partners to provide that layer. But as customer demand accelerated, existing financing products repeatedly failed to fit the economics and needs of the market.
So BioEsol built that capability into the platform itself, adding financing as the fourth layer alongside generation, storage, and energy management, and allowing the company to turn customer demand into long-term, financeable infrastructure.
The problem: demand is outrunning the grid, with nobody financing the middle
BioEsol sells distributed solar-and-storage systems to commercial and industrial (C&I) customers in Mexico, mostly companies spending between $60,000 and $1.2 million a year on energy. That segment sits in a gap that Felipe describes from experience: a $500,000 or $1 million distributed-energy project can make perfect sense for the customer and still be inefficient for an institutional lender to diligence, structure, and monitor on its own, a problem that only compounds once you're talking about hundreds of customers instead of one. The result is a segment too small for infrastructure funds to underwrite deal-by-deal, and largely passed over by banks and existing energy providers, who tend to offer power-purchase agreements with better pricing but no resilience against outages. Mexico's grid, meanwhile, hasn't seen major government investment in six years by Felipe's account; at the same time, a wave of manufacturers from China, Japan, South Korea, France and many more are trying to build facilities in Mexico to serve the U.S. market, facilities that need reliable power the grid isn't guaranteed to supply. Felipe says his team is now working directly with state energy secretaries, fielding pressure from exactly these companies.
Solar alone doesn't close that gap. Felipe says more than 95% of the companies BioEsol has evaluated that already have solar panels have no battery behind them, which means they're still exposed to every outage and price swing on the grid, the exact failure mode BioEsol was built to remove. The value, in his telling, comes from combining onsite generation, storage and intelligent energy management into one system that lowers costs, improves resilience and makes energy predictable. The harder part, he says, is financing it.
As Felipe frames it, the customer need is real, the technology already exists, and increasingly so does the capital looking for exactly this kind of infrastructure. What's missing, in his view, is a repeatable system for turning thousands of individual energy needs into financeable assets, standardized, underwritten, monitored, and eventually bundled into portfolios institutional capital can actually buy into. That, more than solar panels or batteries specifically, is increasingly how he describes the business BioEsol is building.
How the model got here
The technology traces back further than the company's 2021 founding date suggests. BioEsol's first battery was installed 15 years ago in an off-grid community in Mexico, an early project of co-founders Samuel and Gabriel, who went on to build a street-lighting company, Biolumina, on the same underlying technology. That business ran on long-term, project-financed public-sector contracts rather than one-off equipment sales, a structure that resurfaces almost exactly in BioEsol today. By 2020, the founders had moved into commercial pilots, hotels in Tulum, that validated a simple but expensive insight: companies with solar already installed still had no way to store that power on-site, and once BioEsol saw that gap, Felipe says, "it was like the whole thesis behind the idea."
BioEsol formally launched in 2021, initially selling solar-plus-storage systems as one-time installations: design it, quote it, install it, collect payment. It worked, revenue grew from roughly $260,000 in the company's first four-month stretch in 2021 to about $15.1 million by fiscal year 2025, and gross margins on that model climbed from roughly 35% to 42%, Felipe says. But starting in late 2023 and into 2024, something in the business stopped adding up: the sales pipeline kept accelerating, growing at what Felipe describes as 200-250% year over year, while the rate of deals actually closing moved in the opposite direction. The bottleneck wasn't the product. It was financing: customers wanted the systems, couldn't front the capital, and the banks BioEsol approached couldn't make a proposal work for either side.
So BioEsol stopped selling equipment to customers who couldn't finance it, and started financing the projects itself.
The model today: Energy-as-a-Service
Felipe describes the financial layer as something the company always planned to embed in its offering, the same way it built its battery supply chain: not by purchasing off-the-shelf units, but through direct technical work validating manufacturers against BioEsol's own specifications. The original assumption was that banks, leasing companies, or other financial partners would supply the financial layer the same way, as a capability built to spec, not a bought commodity; when their products didn't match what the market actually needed, BioEsol built that capability itself, developing its own credit-analytics tools, including early neural-network models designed to underwrite a customer's trajectory over time rather than a single financial snapshot.
Under the model BioEsol runs today, the company underwrites a prospective customer through that credit analysis, signs a 10-to-15-year contract, and funds the CAPEX itself. It isn't a traditional per-kWh power-purchase agreement — the customer pays a fixed monthly service fee instead. The infrastructure and the associated debt sit in dedicated SPV/AssetCo structures, off BioEsol's own balance sheet, secured against the customer contract and backed by a fraud-insurance policy. Felipe's own example is a company that was paying $10,000 a month in variable energy costs, now paying $7,000 flat, a roughly 30% reduction from month one, escalated for inflation over the life of the contract. BioEsol recovers its CAPEX and financing costs within three years, Felipe says, and keeps roughly 90% gross margin, blended, for the remainder of the term.
BioEsol doesn't manufacture its own hardware; Felipe compares the approach explicitly to Apple's outsourced-manufacturing model, though it's not simply buying commodity parts off the shelf. Building the battery relationship took more than a year of direct technical work: validating functionalities, voltage, connectivity, and communication with BioEsol's own system, and negotiating the cost structure, inventory commitments, and priority technical response that now come with the alliance. Today that means working with three of the world's top ten battery manufacturers on those terms. Solar panels are a more straightforward purchase: commodity-grade, tier-one panels bought from international and national suppliers. What the company builds fully in-house is the energy management software, and the communications and performance algorithms, developed by teams in both Mexico and France, that run the batteries and adapt to each customer's consumption profile, the piece BioEsol treats as its real technical moat.
The business-model implication is the part Felipe returns to most. A one-time equipment sale ends the day the installation is paid for; a 10-to-15-year service contract keeps generating payments for over a decade, backed by a physical, operating asset. Enough of those contracts, running at once, and BioEsol isn't just selling energy equipment anymore; it's building a portfolio of contracted infrastructure.
What's operating today
Strip away the narrative, and the numbers — drawn from BioEsol's own September 2026 investor teaser and from Felipe directly — still have to hold up on their own:
$15.1 million in FY2025 revenue, the company's fifth consecutive year of revenue and its first year of positive EBITDA, up from roughly $260,000 in that first four-month stretch in 2021
300+ companies served historically, including Enel, Foxconn and Decathlon (the teaser notes some of these may reflect past one-time equipment sales, not necessarily current EaaS customers)
14 operating EaaS projects, plus 3 more in commissioning — together part of a near-term, 17-project cohort worth roughly $1.98 million in average annual contract value and $15.1 million in total contractual value
29 customer-awarded projects worth $168.8 million in total contractual value, backed by 46.6 MWh of battery storage and 8.7 MWp of solar capacity, and requiring about $24 million of deployment CAPEX — signed by customers, but still pending contract execution and financing activation, not booked revenue
336 qualified pipeline opportunities worth roughly $201 million in quoted value, across 23 Mexican states, with 95 already at engineering stage or beyond
A $10 million institutional asset facility signed and deploying, with a further $31 million in asset-level financing structure under signed indicative terms, subject to due diligence and closing
BioEsol describes this internally as "14 → 17 → 29 → 336" — operating projects, the near-term cohort moving through commissioning, awarded-but-unfinanced projects, and the broader qualified pipeline behind them. Each stage dwarfs the one before it. The gap Felipe keeps returning to isn't demand; it's the deployment capital needed to move a project from "awarded" to "operating."
That's also why Felipe resists being measured the way investors typically size up a software company. Annual recurring revenue understates what's actually being built, he argues; the real asset is the contracted infrastructure cash flow sitting behind it: how much has been originated, how much debt that stream can support, what's left after debt service. A single $500,000 project is too small for most institutional investors to look at twice. A diversified $100 million portfolio of standardized, monitored, contracted assets is a different conversation entirely, and getting from the first to the second, Felipe says, is exactly the transition BioEsol is trying to accelerate.
What one project actually looks like
One of BioEsol's projects currently in commissioning gives a sense of the unit economics behind those totals: roughly 699 kWh of battery storage and 300 kWp of solar PV, about $502,000 of deployment CAPEX, and a 15-year contract starting at roughly $12,200 a month and escalating over the term, a total contractual value near $4.15 million. Across the three-project commissioning cohort, that adds up to about $1.5 million of deployment CAPEX generating $12.4 million in total contractual value.
Felipe is careful about what that ratio does and doesn't mean: total contractual value isn't profit, and project OPEX, financing costs, reserves, taxes, and debt service all sit between a signed contract and equity returns. But the underlying mechanic is the one BioEsol is betting on: a relatively modest amount of upfront infrastructure capital creates a long-duration, contracted payment stream. Run that across hundreds of projects instead of one, and it starts to look less like a collection of installations and more like an asset class.
Grenoble, and why France exists
BioEsol's European presence started almost by accident. In 2022, a year after founding, the company went through Techstars' accelerator program in Paris. That connection led to an introduction from Business France, the government's investment promotion agency, which was actively courting startups focused on climate resilience and energy autonomy in the aftermath of the war in Ukraine's impact on European energy prices. A scouting trip to Grenoble in January 2023, a week of meetings with the local startup, university, banking, and R&D ecosystem, convinced the founders they'd found, in Felipe's words, "one of the best places, not only in France, but in Europe and maybe in the world," for renewable energy and battery research. BioEsol opened an R&D office there and picked up early non-dilutive grants from BPI, France's public investment bank.
The company has evolved alongside that footprint. BioEsol is today structured as a French company, with a French holding company, commercial operations based in Mexico and R&D based in France, and it's now in the process of standing up commercial operations in France as well.
The teaser is explicit, though, that Mexico, not France, is "the core underwriting case." BioEsol is currently structuring its first French project, an industrial facility with a data-center component, which Felipe says the team is working to close in the short term, prompted in part by a French regulatory change that has exposed small-scale energy generators to negative pricing during parts of the day. For a French or European company facing that kind of pricing volatility, Felipe says the appeal is the same one that brings customers to BioEsol in Mexico: avoiding the upfront CAPEX lets them decarbonize their operations while getting the tools to manage that pricing risk, rather than taking on the investment and the engineering themselves. The company treats France as evidence that its architecture travels to a different regulatory environment, not as a second growth market investors should be underwriting today.
The raise
BioEsol is running a staged equity process targeting up to €30 million, structured so it can close in smaller amounts across multiple investors rather than requiring one large check; Felipe was explicit on the call that the raise doesn't need to land in a single close. Roughly half the proceeds, he says, will fund BioEsol's own equity contribution into upcoming projects: debt typically covers 70-80% of project CAPEX, leaving BioEsol to fund the remaining 20-30% to convert its awarded pipeline into operating assets. The other half is earmarked for hiring. The team has held at 28 people for two years, deliberately, Felipe says, calling BioEsol "a lean company", and plans to grow to 40-45, adding people specifically in project finance, structuring and engineering rather than expanding headcount broadly.
Felipe frames the €30 million as one half of a two-part capital structure, not the whole of it. The equity raise strengthens BioEsol itself, the underwriting team, the engineering capability, the systems that originate and structure deals. Separately, and at the same time, the company is building out asset-level financing capacity to fund the infrastructure that engine produces: on top of the $10 million facility already signed and the $31 million under indicative terms, BioEsol is now working to structure roughly $40-50 million of additional asset-level financing. Felipe is specific about what that capital is for: capturing the demand already sitting in BioEsol's awarded and qualified pipeline and converting it into financeable assets backed by long-term, recurring-revenue contracts, rather than funding growth in the abstract. The distinction matters to how Felipe wants investors to think about leverage: platform equity builds the machine; asset-level debt finances what the machine produces. Done right, each euro raised at the holding-company level helps mobilize several euros of infrastructure capital behind it.
Felipe says he's targeting venture capital, private equity or infrastructure funds, impact funds, or fintech-focused VCs, investors who understand both the energy transition and the credit realities facing small and mid-sized businesses. He's also candid about process speed as a filter: development banks and institutions like the European Investment Bank, he says, have quoted him timelines of eight months to a year and a half to close, and he wants a partner who can move in two to three months, because in his words, "the opportunities here, it's all about timing." As of the September call, BioEsol has multiple prospective investors already engaged.
What investors are being asked to underwrite
BioEsol isn't asking anyone to bet on unproven demand. It has five years of revenue and positive FY2025 EBITDA, 300-plus customers served, and a signed pipeline worth more than ten times its current $10 million facility. What's still open is the capital question: whether BioEsol can raise equity and debt fast enough to turn a $168.8 million awarded pipeline, and a $201 million qualified pipeline behind it, into operating, cash-collecting assets before that gap turns from an opportunity into a ceiling.
The bet
BioEsol didn't set out to become a lender. It became one because that was the only way to get its own product into the hands of the customers who needed it most; the company is quick to note it isn't trying to become a bank either. The assets are physical, the engineering has to work, and the equipment has to run every day for the contract to pay out. Whether that makes BioEsol a fintech company, an energy company, or something in between is, in a way, beside the point; the company has already proven it can originate, underwrite, deploy, and collect on real contracts, at a real (if still asset-constrained) scale. The question for investors isn't whether the demand is real. It's whether they want to fund the machine that turns it into contracted, financeable infrastructure, or wait for someone else to.
Felipe says BioEsol already has multiple prospective investors in conversation, but no lead has signed yet, and given the two-to-three-month process he's optimizing this raise around, that window isn't likely to stay open for long.
BioEsol at a Glance
What it does: Distributed energy infrastructure (solar + battery storage) delivered as a service to commercial & industrial customers
Where: Core market Mexico; France is the R&D base and first European reference market
Founded: 2021; structured today as a French company, with commercial operations in Mexico and R&D in France
Founders: 4 — Samuel & Gabriel (Mexico, CEO/CFO, previously built street-lighting energy company Biolumina, still operating; serving on its board) — Felipe Arriola (France, President; 5th startup, 2 prior exits in software and foodtech) — Alejandra (France, Chief Sustainability Officer; 3rd startup, 1 prior exit in foodtech, previously at Mars)
Team size: 28 people, targeting 40-45
Customer profile: C&I SMBs spending $60K–$1.2M/year on energy
FY2025 revenue: $15.1M (5th year with revenues)
Profitability: Positive FY2025 EBITDA
Companies served historically: 300+, including Enel, Foxconn, Decathlon
Business model: Energy-as-a-Service — 10–15 year contracts, fixed monthly payments, assets held off-balance-sheet in SPVs
Operating projects: 14 live, 3 in commissioning
Awarded pipeline: 29 customer-awarded projects, $168.8M total contractual value, 46.6 MWh storage / 8.7 MWp solar (pending financing activation)
Broader pipeline: 336 qualified opportunities, ~$201M quoted value, across 23 Mexican states
Financing in place: $10M asset facility signed/deploying; $31M asset-level finance structure, under signed indicative terms
Additional financing objective: $40-50M of further asset-level financing to convert awarded/qualified pipeline into financeable assets under recurring-revenue contracts
Prior funding: Pre-seed (Techstars, Catapult, a US VC, Mexican family office) + $5M seed led by a Hong Kong / Paris family office, $30M post-money
Current raise: Up to €30M equity, staged closes accepted
Use of funds: 50% project equity co-investment, 50% hiring (finance, ops, engineering), accelerating commercialization strategy
Investor profile sought: VC / PE / infra / impact / fintech-focused funds comfortable with a 2-3 month process
Status: No lead investor signed yet as of the September call
Based on a direct interview with BioEsol president Felipe Arriola (September 2026) and BioEsol's September 2026 investor teaser. All figures are as reported by BioEsol and have not been independently verified.
